T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel
By Dr. Matthew Watson
LEXINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii.
Read the original here:
T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel
Related Post
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally - December 18th, 2024
- Vaccinex Announces Receipt of Delisting Notification from Nasdaq - December 18th, 2024
- Adia Nutrition Unveils Exclusive Artwork by Renowned Performance Artist Rock Demarco at First Clinic - December 18th, 2024
- NYMOX Announces Trading Resumed and New Listing on OTCQB Market - December 18th, 2024
- Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy - December 18th, 2024
- AB Science provides a summary of the webcast held on December 16, 2024 - December 18th, 2024
- Ultimovacs ASA – Mandatory notification of trade - December 18th, 2024
- Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare... - December 18th, 2024
- Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA - December 18th, 2024
- Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference - December 18th, 2024
- Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18,... - December 18th, 2024
- Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity - December 18th, 2024
- Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - December 18th, 2024
- electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic... - December 18th, 2024
- Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - December 18th, 2024
- NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - December 18th, 2024
- AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - December 18th, 2024
- Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - December 18th, 2024
- NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology - December 18th, 2024
- Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution - December 18th, 2024
- Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP - December 9th, 2024
- Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s... - December 9th, 2024
- Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting - December 9th, 2024
- Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory... - December 9th, 2024
- Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on... - December 9th, 2024
- Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal... - December 9th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or... - December 9th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With... - December 9th, 2024
- DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with... - December 9th, 2024
- Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin... - December 9th, 2024
- Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic... - December 9th, 2024
- C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become... - December 9th, 2024
- Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML - December 9th, 2024
- Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma - December 9th, 2024
- Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th... - December 9th, 2024
- Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat - December 9th, 2024
- Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’ - December 9th, 2024
- Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function - December 9th, 2024
- AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related... - December 9th, 2024
- Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders - December 9th, 2024
- Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives - November 29th, 2024
- CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - November 29th, 2024
- Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 29th, 2024
- Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel - November 29th, 2024
- Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 29th, 2024
- PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area - November 29th, 2024
- SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers - November 29th, 2024
- Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - November 29th, 2024
- Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates - November 29th, 2024
- Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 - November 29th, 2024
- Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - November 29th, 2024
- QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis - November 29th, 2024
- Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq - November 29th, 2024
- Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia - November 29th, 2024
- Celularity Inc. Announces Receipt of Nasdaq Notification - November 29th, 2024
- HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms - November 29th, 2024
- Kane Biotech Announces Third Quarter 2024 Financial Results - November 29th, 2024
- Rakovina Therapeutics Announces Private Placement Offering - November 29th, 2024
- MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS) - November 29th, 2024
- Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million - November 29th, 2024
- Panbela Provides Business Update and Reports Q3 2024 Financial Results - November 15th, 2024
- Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability - November 15th, 2024
- Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - November 15th, 2024
- TFF Pharmaceuticals Announces It Will Wind Down Operations - November 15th, 2024
- Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - November 15th, 2024
- GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for... - November 15th, 2024
- Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update - November 15th, 2024
- HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights - November 15th, 2024
- Lowell Farms Inc. Announces Unaudited Third Quarter 2024 Financial and Operational Results - November 15th, 2024
- Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons... - November 15th, 2024
- UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials - November 15th, 2024
- Avicanna Reports Q3 2024 - November 15th, 2024
- Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - November 15th, 2024
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in... - November 15th, 2024
- Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - November 15th, 2024
- Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) - November 15th, 2024
- Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio - November 15th, 2024
- Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - November 15th, 2024
- NINER Pharmaceutical Strengthens Global Presence with Strategic IV Fluid Supply Initiative for the U.S. and Latin American Markets - November 15th, 2024
- Bavarian Nordic Announces Interim Results for the First Nine Months of 2024 - November 15th, 2024
Global News Feed
Comments Off on T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel |
October 21st, 2022
This author published 5912 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research